This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cyclacel Pharmaceuticals Croissance future
Future contrôle des critères 5/6
Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 52.2% and 57.5% per annum respectively while EPS is expected to grow by 46.4% per annum.
Informations clés
52.2%
Taux de croissance des bénéfices
46.4%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 35.0% |
Taux de croissance des recettes | 57.5% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 17 Jan 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 56 | 25 | N/A | N/A | 1 |
12/31/2025 | N/A | -27 | N/A | N/A | 1 |
12/31/2024 | N/A | -24 | N/A | N/A | 2 |
12/31/2023 | 0 | -23 | N/A | N/A | 3 |
9/30/2023 | 0 | -25 | -17 | -17 | N/A |
6/30/2023 | 0 | -24 | -20 | -20 | N/A |
3/31/2023 | N/A | -23 | -21 | -21 | N/A |
12/31/2022 | N/A | -21 | -21 | -21 | N/A |
9/30/2022 | N/A | -19 | -20 | -20 | N/A |
6/30/2022 | N/A | -19 | -19 | -19 | N/A |
3/31/2022 | N/A | -20 | -22 | -22 | N/A |
12/31/2021 | N/A | -19 | -19 | -19 | N/A |
9/30/2021 | N/A | -20 | -15 | -15 | N/A |
6/30/2021 | N/A | -18 | -11 | -11 | N/A |
3/31/2021 | N/A | -15 | -9 | -9 | N/A |
12/31/2020 | N/A | -12 | -8 | -8 | N/A |
9/30/2020 | N/A | -8 | -8 | -8 | N/A |
6/30/2020 | N/A | -8 | -8 | -8 | N/A |
3/31/2020 | N/A | -7 | -9 | -9 | N/A |
12/31/2019 | N/A | -8 | -9 | -9 | N/A |
9/30/2019 | 0 | -8 | -10 | -10 | N/A |
6/30/2019 | 0 | -8 | -9 | -9 | N/A |
3/31/2019 | 0 | -8 | -8 | -8 | N/A |
12/31/2018 | 0 | -7 | -7 | -7 | N/A |
9/30/2018 | N/A | -8 | -7 | -7 | N/A |
6/30/2018 | N/A | -14 | -7 | -7 | N/A |
3/31/2018 | N/A | -15 | -6 | -6 | N/A |
12/31/2017 | N/A | -15 | -7 | -7 | N/A |
9/30/2017 | 0 | -16 | -8 | -8 | N/A |
6/30/2017 | 0 | -10 | N/A | -10 | N/A |
3/31/2017 | 1 | -11 | N/A | -11 | N/A |
12/31/2016 | 1 | -12 | N/A | -10 | N/A |
9/30/2016 | 1 | -13 | N/A | -10 | N/A |
6/30/2016 | 1 | -12 | N/A | -11 | N/A |
3/31/2016 | 2 | -13 | N/A | -13 | N/A |
12/31/2015 | 2 | -15 | N/A | -14 | N/A |
9/30/2015 | 2 | -16 | N/A | -15 | N/A |
6/30/2015 | 2 | -18 | N/A | -18 | N/A |
3/31/2015 | 2 | -20 | N/A | -19 | N/A |
12/31/2014 | 2 | -20 | N/A | -19 | N/A |
9/30/2014 | 2 | -18 | N/A | -20 | N/A |
6/30/2014 | 1 | -19 | N/A | -16 | N/A |
3/31/2014 | 1 | -13 | N/A | -18 | N/A |
12/31/2013 | 1 | -20 | N/A | -18 | N/A |
9/30/2013 | 1 | -21 | N/A | -15 | N/A |
6/30/2013 | 1 | -18 | N/A | -15 | N/A |
3/31/2013 | 0 | -23 | N/A | -14 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: UXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Bénéfices vs marché: UXI is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: UXI is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: UXI's revenue (57.5% per year) is forecast to grow faster than the German market (5.4% per year).
Croissance élevée des revenus: UXI's revenue (57.5% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if UXI's Return on Equity is forecast to be high in 3 years time